De-Risk Development And Manufacture Of Bispecific Antibodies With Lonza

Source: Lonza

By Alice Harrison, Director, Global Technical & CMC, Analytics, Lonza


There is growing demand for multi-chain protein biotherapeutics such as bispecific antibodies (bsAbs) which offer promising treatments for cancers and other diseases. But assembling and expressing bsAbs to advance them for first-in-human (FIH) trials comes with a set of unique challenges.

This article will explore how to meet those challenges head-on by partnering with a contract development and manufacturing organization (CDMO) that has proven expertise and a toolbox of technologies designed for peak performance with these novel molecular formats.

access the Article!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Bioprocess Online? Subscribe today.

Subscribe to Bioprocess Online X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.


Subscribe to Bioprocess Online